ALK and non-small cell lung carcinoma: Based on these positive data, tiragolumab received breakthrough therapy designation by FDA [168] for first-line treatment of NSCLC patients with high tumor PD-L1 expression and no EGFR or ALK mutations, thus making it an excellent candidate to reach the market in a near future.